AstraZeneca to show 'exceptional' data on neuromyelitis drug Ultomiris

(Alliance News) - AstraZeneca PLC on Wednesday said its subsidiary Alexion Pharmaceuticals Inc, ...

Alliance News 12 October, 2022 | 9:47AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Wednesday said its subsidiary Alexion Pharmaceuticals Inc, which focuses on rare diseases, will publish "new data showing significant advances" regarding the treatment for a form of neuromyelitis with its drug Ultomiris.

The specific disease targeted is anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, or NMOSD, a rare condition with which the immune system damages the spinal cord and the optic nerves.

The Cambridge, England-based pharmaceutical company said that during a 73-week treatment period, no NMOSD patients on Ultomiris showed a worsening of their condition, known as relapse. This represents a near 99% reduction risk compared to a placebo. Safety and tolerability data were consistent with previous clinical studies. All tested patients were adults.

AstraZeneca will publish its data between October 26 and 28 at the European Committee for Treatment & Research in Multiple Sclerosis Congress.

AstraZeneca shares were 2.2% higher at 10,038.00 pence each in London on Wednesday morning.

By Tom Budszus; tombudszus@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 10,938.00 GBX 0.87

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures